BioViva USA has secured a US patent covering the combined use of hTERT and Follistatin-344, delivered via viral vectors such as AAV, with claims naming telomere length, muscle mass and blood-glucose regulation as intended outcomes. The filing reflects a strategy that treats age-related decline itself as the therapeutic target rather than its individual disease endpoints. The combination remains investigational, with no regulatory approval and no established safety or efficacy data.
Key Points
- Patent covers hTERT and Follistatin-344 used in combination
- Claimed targets: telomere length, muscle mass, blood glucose
- Intellectual property only — no approval, safety or efficacy established
Longevity Analysis
Pairing telomere maintenance with a modulator of muscle and tissue pathways reflects a broader shift toward upstream intervention, where cellular replicative capacity, lean mass preservation and glucose handling are treated as one interconnected decline rather than three separate clinical problems. Frailty, metabolic dysregulation and impaired tissue renewal develop along shared timelines, and interpreting them as a single trajectory changes what is worth measuring decades before diagnosis. Gene therapy of this kind sits far from clinical availability, which leaves the practical lever in the same place it has always been — sustained control of the inputs that govern muscle retention and glucose stability over time.
Original published by Longevity.Technology, by Kyle Umipig.